Last Published:  07/31/19 10:05:30 AM (Central)
Responsible Element: Space Radiation (SR)
Status: Open
Description

Initial State of Gap:

The contributions of individual sensitivity (genetic, epigenetic, previous injury, age, sex/gender, etc.) to possible acute and late risks to the CNS from space radiation exposure are undetermined.

 

Approach:

    Ground-based, peer-reviewed research using cell and animal models to acquire necessary knowledge for accurate risk quantification and uncertainty reduction on impacts of individual sensitivity and previous CNS injury on CNS risks due to space radiation exposure. Where feasible, identify biomarkers of disease prognosis/progression or biomarkers predicting individual sensitivity and for use in BCM selection as required.

Interim Steps:

 

  • Determine impact of individual susceptibility on space radiation dose responses, possible dose thresholds, latency to onset and severity of acute and late CNS effects
  • Determine impact of previous CNS injury on space radiation dose responses, possible dose thresholds, latency to onset and severity of acute and late CNS effects
  • Determine feasibility of indexed biomarker approaches for monitoring individual susceptibility for acute and late CNS effects of concern
  • Acquire data from astronauts to relate space radiation exposure and individual sensitivity to acute and late CNS outcomes      
       

Target for Closure
  • Identification of factors that would affect individual risk (both acute and late) to the CNS from space radiation exposure and assessment of these factors in a study in astronauts.
  • Identify biomarkers linking individual sensitivity factors to outcome measures.
Mappings
Risk Risk of Adverse Cognitive or Behavioral Conditions and Psychiatric Disorders
Risk Risk of Acute (In-flight) and Late Central Nervous System Effects from Radiation Exposure
You are here! Gap CBS-CNS - 3: How does individual susceptibility including hereditary pre-disposition (e.g. Alzheimer’s, Parkinson’s, apoE allele) and prior CNS injury (e.g. concussion, chronic inflammation or other) alter significant CNS risks? Does individual susceptibility modify possible threshold doses for these risks in a significant way?
Active
Completed
Planned-Funded

Documentation:
No Documentation Available